HSBC Maintains Zoetis(ZTS.US) With Buy Rating, Cuts Target Price to $180
Leerink Partners Adjusts Price Target on Zoetis to $190 From $200, Maintains Outperform Rating
BofA Securities Maintains Zoetis(ZTS.US) With Buy Rating, Announces Target Price $200
Bank of America Securities Keeps Their Buy Rating on Zoetis (ZTS)
Stifel Maintains Zoetis(ZTS.US) With Buy Rating, Cuts Target Price to $165
Zoetis Is Maintained at Buy by Stifel
Zoetis Analyst Ratings
Piper Sandler Maintains Zoetis(ZTS.US) With Buy Rating, Maintains Target Price $205
Piper Sandler Remains a Buy on Zoetis (ZTS)
BTIG Maintains Zoetis(ZTS.US) With Buy Rating, Maintains Target Price $200
BTIG Sticks to Their Buy Rating for Zoetis (ZTS)
Zoetis Analyst Ratings
BNP Paribas Exane Adjusts Price Target on Zoetis to $219 From $232, Keeps Outperform Rating
Piper Sandler Maintains Zoetis(ZTS.US) With Buy Rating, Raises Target Price to $205
Stifel Maintains Zoetis(ZTS.US) With Buy Rating, Maintains Target Price $180
Zoetis' Strong Market Position and Growth Potential Justify Buy Rating
Analysts Offer Insights on Healthcare Companies: Zoetis (ZTS), Arcutis Biotherapeutics (ARQT) and Insulet (PODD)
BTIG Maintains Zoetis(ZTS.US) With Buy Rating, Maintains Target Price $200
BofA Securities Maintains Zoetis(ZTS.US) With Buy Rating
BTIG Maintains Zoetis(ZTS.US) With Buy Rating, Cuts Target Price to $200